Clinician-Scientist Program

In the Spring of 2009, Prostate Cancer Canada offered a limited number of awards to provide salary and research support for outstanding Clinician-Scientists initiating a career as independent investigators/junior faculty in prostate cancer research. These awards provide the opportunity for new faculty with three or fewer years of service as independent investigators to develop and demonstrate independence in initiating and conducting prostate cancer research. Candidates for the Prostate Cancer Canada Clinician-Scientist award must:
  • hold an M.D. degree or equivalent;
  • be licensed to practice medicine in Canada; and
  • be nominated by a hospital-affiliated research institution.
Prostate Cancer Canada will make a maximum total contribution of $150,000 per year, per award, for up to two years
What does a Clinician-Scientist do?
Clinician-Scientists are essentially scientists who are clinically trained and may do a small amount of clinical work, but their core focus is research in their given  discipline (e.g. medical oncology, radiation, uro-oncology etc.) Clinician-Scientists have a background that supports translation from basic science to clinical practice and they link closely with clinician researchers. These individuals not only require their clinical training, but usually have a PhD or equivalent  additional training. 
Clinician-Scientists make a major contribution in the translation of research knowledge into improved patient care and health. Their research flows from bench to bedside to community. They also translate advances in technology and fundamental understanding of disease processes to situations that are clinically faced on a daily basis.  They ensure rapid knowledge translation across the continuum from discovery to application to policy.   Clinician-Scientists are critical to this research process as they function between disciplines and encourage collaboration between basic science and clinical research communities. In today’s world of “evidence based” treatments, the clinician-scientist is ultimately required to gather the evidence.

2012 Request for Applications: Clinician-Scientist Program

1. Program Objective
This Request for Applications (RFA) is intended to support research for Clinician-Scientists initiating a career as an investigator/junior faculty in prostate cancer research.

2. Mechanisms of Support
The Clinician-Scientist Award has a length of 2 years and a value of $150,000/year

3. Program Eligibility
In order to apply for this award, applicants must:

  • have five years or less of service as an independent investigator within the area of prostate cancer research
  • possess an M.D. degree or equivalent
  • be licensed to practice medicine in Canada 
  • be nominated by a hospital-affiliated research institution
  • candidates who are currently in training must start as faculty in July 2012 in order to be eligible to apply


4. Applications
To apply, applicants must fill out an online application form which will be found on the Prostate Cancer Canada website: Application.

5. Important Dates
Competition Opens    January 3, 2012
Application Deadline  March 15, 2012 at 5pm EST. 
Notice of Decision      June 29, 2012
Funding Start Date     July 3, 2012  

6. Contact      
Joanne Reynolds, Manager Grants & Awards
Prostate Cancer Canada 
2 Lombard Street, 3rd Floor
Toronto, Ontario, M5C 1M1
416-441-2131 Ext. 226


Subscribe to our free monthly e-newsletter!

* indicates required


PCC Spotlight
RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.

Prostate Cancer Canada announces new President and CEO

Toronto, December 21, 2017 – After five successful years under the leadership and guidance of outgoing President and CEO, Rocco Rossi, Prostate Cancer Canada (PCC) is excited to announce the appointment of a most worthy successor in Peter Coleridge, past national CEO of the Canadian Mental Health Association and current national President and CEO of Big Brothers Big Sisters of Canada.

Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.

Click here for news archive